Non technical summary Cholecystokinin (CCK) is a widely expressed neuropeptide known to play key roles in both normal behaviour and pathophysiological conditions. Previous reports suggested that CCK serves as a unique molecular switch that differentially regulates the output of distinct types of inhibitory interneurons in the hippocampus. The current study focused on the underlying mechanisms of the CCK actions on hippocampal interneurons, and the results show that CCK modulates transmitter release from a major class of interneurons through cannabinoid type-1 receptor signalling mechanisms. Taken together, the present data will help us better understand how CCK modulates neuronal circuits in the brain.
Abstract Cholecystokinin (CCK) is an abundant neuropeptide involved in normal behaviour and pathophysiological conditions. Recently, CCK was shown to act as a molecular switch for perisomatic inhibition in the hippocampus, by directly depolarizing parvalbumin expressing (PV + ) basket cells while indirectly depressing GABA release from CCK expressing (CCK + ) basket cells. However, whether these two CCK-mediated effects are causally related is controversial, with one hypothesis proposing that the CCK-induced firing of PV + basket cells increases the release of GABA, which, in turn, heterosynaptically inhibits GABA release from neighbouring CCK + basket cell terminals through presynaptic GABA B receptors. Our present data from paired recording experiments from presynaptic basket cells and postsynaptic CA1 pyramidal cells in acute rat brain slices show that the P/Q Ca 2+ channel antagonist agatoxin TK (250 nM) abolished GABA release from PV + basket cells, but it had no effect on the CCK-induced depression of GABA release from CCK + basket cells. Furthermore, CCK decreased GABA release from CCK + basket cells even in the presence of the GABA B receptor antagonist CGP55845 (2 μM). In contrast, cannabinoid type-1 (CB1) receptor blockade with AM251 (10 μM) prevented the action of CCK on GABA release both from CCK + basket cells and dendritically projecting, CCK + Schaffer collateral-associated interneurons. These results demonstrate that CCK-mediated inhibition of GABA release from CCK + cells requires no cross-talk between PV + and CCK + synapses, but that it critically depends on CB1 receptor-mediated endocannabinoid signalling at both perisomatic and dendritic inputs. Introduction Cholecystokinin (CCK) is expressed at unusually high levels (in microgram quantities) in neuronal circuits in the brain, acting as a functionally important, versatile, cell type-specific neuromodulator acting through G-protein coupled CCK B receptors (for reviews, see Noble & Roques, 2006; Lee & Soltesz, 2011) . The effects of CCK on principal cells include the enhancement of glutamate release through presynaptic mechanisms, often without direct excitatory actions on somato-dendritic domains (Cox et al. 1995; Miller et al. 1997; Földy et al. 2007; Chung & Moore, 2009; Deng et al. 2010 ; but see Boden & Hill, 1988) . In addition, CCK shows diverse, highly cell type-specific actions on GABAergic neurons. Of particular interest in this regard are the effects of CCK on basket cells (BCs) that are strategically placed to regulate the excitability of the perisomatic region of postsynaptic neurons and perform a variety of key operations in the network (Freund & Katona, 2007; Bartos et al. 2007; Ellender & Paulsen, 2010) .
In the hippocampus and neocortex, there are two major, non-overlapping, functionally distinct types of BCs, the parvalbumin expressing (PV + ) and the CCK expressing (CCK + ) basket cells (BCs). PV + BCs appear to be well-suited to entrain network oscillations, because they fire non-accommodating, fast action potentials, have fast membrane time constants, and respond reliably to excitatory inputs, and their GABA release is tightly coupled to intracellular Ca 2+ rises through P/Q Ca 2+ channels (Wilson et al. 2001; Hefft & Jonas, 2005; Glickfeld & Scanziani, 2006) . In contrast, CCK + BCs are thought to primarily serve as modulators that adapt circuit activity to behavioural states, as they fire accommodating spikes, express receptors for various neuromodulators, possess slower membrane time constants, and receive weak excitatory inputs that integrate over long time windows, and GABA release from their terminals is regulated by N-type Ca 2+ channels with a looser coupling between the Ca 2+ source and sensor (Wilson et al. 2001; Hefft & Jonas, 2005; Klausberger et al. 2005; Glickfeld & Scanziani, 2006) . Although these distinctions imply that these two perisomatic GABAergic synaptic control systems function largely independently and in parallel, there is increasing evidence for coordination between PV + BCs and CCK
+
BCs. In addition to the existence of synaptic contacts between PV + BCs and CCK + BCs (Acsady et al. 2000; Karson et al. 2009 ), CCK itself has been shown by recent studies to act as an agent of coordination between PV + BCs and CCK + BCs by gating their outputs in a diametrically opposite fashion . Namely, CCK has been demonstrated to act as a switch that determines the source of perisomatic inhibition for hippocampal principal cells by powerfully increasing the output of PV + BCs through a strong depolarizing effect on these neurons, while inhibiting GABA release from CCK + BCs. Because PV + BCs appear to be especially suited to serve functions related to hippocampal network oscillations and memory (Glickfeld & Scanziani, 2006; Freund & Katona, 2007) , the CCK-mediated gating of perisomatic inhibition may favour tasks requiring precise timing and integration over narrow time windows.
However, exactly how CCK attenuates GABA release from CCK + BCs is not fully understood (Fig. 1 ). According to one view (referred to as the 'GABA B receptor hypothesis' in this paper), the CCK-induced robust increase in PV + BC discharges is a key step in leading to the CCK-mediated inhibition of GABA-release from CCK + BCs (Karson et al. 2008) . Specifically, GABA released from PV + BCs, resulting from the powerful depolarization and action potential discharge of PV + BCs by CCK, is proposed to reach and activate GABA B receptors located on the axon terminals of CCK + BCs, leading to heterosynaptic inhibition of GABA release. In contrast, there is also evidence for an alternative mechanism (referred to as the 'CB1 receptor hypothesis') where the CCK-induced depolarization and action potential discharge in PV + BCs is independent of the CCK-mediated inhibition of GABA release from CCK + BCs ). In the latter scenario, CCK would activate G q/11 -coupled CCK B receptors on postsynaptic pyramidal cells, leading to the synthesis and release of endocannabinoids that retrogradely cross the synaptic cleft and bind to presynaptic CB1 receptors, resulting in inhibition of GABA release from CCK + BCs (Fig. 1) . Because of the potential importance of the CCK-mediated regulatory mechanisms gating distinct perisomatic inhibitory streams in both normal functions and diseased states Lee et al. 2010) . Pyramidal cells (whole-cell voltage clamp configuration, the holding potential was −70 mV) were recorded with internal solution containing (mM) 40 CsCl, 90 potassium gluconate, 1.8 NaCl, 1.7 MgCl 2 , 3.5 KCl, 0.05 EGTA, 10 Hepes, 2 ATP-Mg, 0.4 GTP-Na and 10 phosphocreatine (pH 7.2, 280-290 mosmol l −1 ). All drugs were obtained from Tocris. Recordings of unitary IPSCs between the presynaptic interneurons and the postsynaptic pyramidal cells were made using MultiClamp 700B amplifiers (Molecular Devices, Sunnyvale, CA, USA). Signals were filtered at 3 kHz using a Bessel filter and digitized at 10 kHz with a Digidata 1440A analog-digital interface (Molecular Devices). Series resistances were carefully monitored, and the recordings were discarded if the series resistance changed >20% or reached 25 M . The recorded traces were analysed using the Clampfit 10.2 software (Molecular Devices). During paired recordings, the frequency of presynaptic stimulation was 10 Hz. Values for the so-called 'effective' unitary IPSC (euIPSC; Neu et al. 2007) amplitudes include both successful events and failures (i.e. euIPSC amplitude is the average of all postsynaptic responses to presynaptic spikes). Spontaneous IPSCs (sIPSCs) were recorded from CA1 pyramidal cells in the presence of the ionotropic glutamate receptor antagonists 10 μM APV and 5 μM NBQX. Because CCK actions on GABAergic transmission are powerful but transient (Deng & Lei, 2006; Földy et al. 2007 ; note that the transiency is most likely due to receptor desensitization that was not studied here), quantification of CCK effects was carried out at three distinct time-points: (1) immediately before CCK application (referred to as 'Control' in the text and figures); (2) at the time of the maximal effect during ), leading to endocannabinoid synthesis. The postsynaptically released endocannabinoid would then bind to presynaptic CB1 receptors located on the axon terminals of CCK + BCs, resulting in suppression of GABA release. In a separate series of events, CCK is proposed to bind to CCK receptors on PV + BCs, causing strong depolarization and firing of PV + BC, leading to sharp increases in the spontaneous IPSC frequency recorded from the CA1 pyramidal cells (e.g. Fig. 1 in Földy et al. 2007) . Right, according to the 'GABA B receptor hypothesis', there is only a single direct action of CCK, namely, the activation of excitatory CCK receptors on PV + BCs, resulting in action potential discharges in PV + BCs. The spiking in PV + BCs, in turn, leads to the release of GABA that reaches and activates presynaptic GABA B receptors on CCK + BCs, resulting in a suppression of GABA release from the CCK + BCs.
CCK application ('Peak'; typically observed about 3 min after the starting of the CCK application, with the peak effect lasting for about 1 min, see Fig. 1 in Földy et al. 2007) ; and (3) more than 5 min after the start of the CCK application, when the response returns to baseline even in the continued presence of CCK ('Postpeak'; e.g. Fig. 2b in Földy et al. 2007 and Fig. 2B of the current paper). Data are presented as means ± S.E.M. Student's t test for paired or unpaired data was used for statistical analysis and significant differences were at the level of P < 0.05.
Immunochemistry and cell identification
After recording, slices were transferred into a fixative solution containing 4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphate buffer. Slices were resectioned into 50 μm thin sections and immunoreactivity for CCK was revealed with a mouse monoclonal antibody (mAb 9303, generously provided by the CURE Digestive Diseases Research Center, Antibody RIA Core, Los Angeles (NIH grant no. DK41301); diluted 1:1000); immunoreactivity for PV was tested with a rabbit polyclonal antibody (PV-28; Swant, Bellinzona, Switzerland; diluted 1:1,000 in Tris-buffered saline containing 2% normal goat serum). The reactions were visualized with a goat anti-rabbit IgG conjugated to Alexa 488 (diluted 1:500 in Tris-buffered saline containing 2% normal goat serum; Molecular Probes/Invitrogen) and a goat anti-mouse IgG conjugated to Alexa 594 (diluted 1:500), streptavidin conjugated to Alexa-350 for biocytin (diluted 1:500). The sections were then mounted in Vectashield (Vector Laboratories, Inc., Burlingame, CA, USA) and analysed with a fluorescence microscope. In order to reveal the axonal and dendritic arbours of the interneurons in detail, the biocytin-filled cells were subsequently visualized with 3,3 -diaminobenzidine tetrahydrochloride (0.015%) using a standard ABC kit (Vector Laboratories). The identification of CCK + BCs, CCK + SCA interneurons, and PV + BCs was based on the distinct axonal morphology (CCK + BCs and PV + BCs: a large proportion of the axons were located within or adjacent to the pyramidal cell layer; SCAs: axons ramify predominantly in the stratum radiatum, and to a lesser extent in the oriens) and the immunopositivity to CCK and immunonegativity to PV for CCK + BCs and SCAs, and the immunopositivity to PV and immunonegativity to CCK for PV + BCs (Vida et al. 1998; Cope et al. 2002; Pawelzik et al. 2002; Hefft & Jonas, 2005; Glickfeld & Scanziani, 2006; Ali, 2007; Földy et al. 2007; Lee et al. 2010; see Figs 2A and 4A Daw et al. 2009 ), in agreement with the location of the GABAergic input synapses along the somato-dendritic axis of the principal cells.
Results
Data in this study were obtained using paired whole-cell patch-clamp recordings from post hoc identified presynaptic CCK + BCs or PV + BCs or CCK + SCA interneurons and postsynaptic CA1 pyramidal cells (in addition, for one set of experiments associated with the measurement of sIPSCs in older animals, single whole-cell patch clamp recordings from CA1 pyramidal cells were employed). All presynaptic interneurons in this paper were identified both anatomically (e.g. perisomatically projecting BCs versus dendritically projecting SCAs) and immunocytochemically (e.g. CCK + or PV + cells). Note that in the current study aiming to test two alternative hypotheses about mechanisms underlying CCK actions on GABAergic transmission, responses to CCK application were tested at only one (high) concentration (500 nM) of CCK, in order to evoke maximal effects on GABAergic transmission (for data on the qualitatively similar nature of the CCK effects on BC transmissions at low and high doses, including a dose-response curve, see Földy et al. 2007 ).
GABA release from PV
+ BCs is not required for the CCK-induced suppression of GABA release from CCK + BCs
First, we confirmed that, as reported previously , bath application of CCK (500 nM) attenuated the amplitude of euIPSCs at CCK + BC ( Fig. 2A ) to CA1 pyramidal cell synapses ( Fig. 2B ; pre-CCK control: −59.1 ± 13.3 pA; CCK peak: −44.2 ± 12.1 pA; postpeak: −56.6 ± 12.4 pA; reduction by CCK: 27.1 ± 6.1%, n = 5; P = 0.01). Next, we tested the validity of a central assumption of the 'GABA B receptor hypothesis' , namely, that GABA release from PV + BCs is required for the CCK-mediated suppression of GABA release from CCK + BCs. PV + BCs, not CCK + BCs, express P/Q-type Ca 2+ channels at their terminals, and selective blockade of P/Q-type Ca 2+ channels with agatoxin TK decreases GABA release from PV + BCs, but not CCK + BCs, in an irreversible manner (Wilson et al. 2001; Hefft & Jonas, 2005; Zaitsev et al. 2007 ). Indeed, even relatively brief (5 min) bath application of agatoxin TK (250 nM) caused a complete suppression of euIPSCs at PV + BC to pyramidal cell synapses, and the effect was not reversible even after prolonged (40 min) washout ( Fig. 2C ; pre-agatoxin TK: −45.7 ± 3.9 pA; agatoxin TK: −0.7 ± 0.3 pA; washout: −0.2 ± 0.2 pA; n = 3; P = 0.007). Importantly, in slices pre-incubated for >1 h in agatoxin TK (250 nM), CCK (500 nM) still attenuated the amplitude of euIPSCs at CCK + BC to pyramidal cell synapses ( Fig. 2D ; pre-CCK control: −104.8 ± 42.3 pA; CCK peak: −76.7 ± 29.8 pA; CCK post-peak: −101.8 ± 40.7 pA; reduction by CCK: 27.3 ± 5.3%, n = 5; P = 0.01). The degree of CCK-induced suppression of GABA release did not differ between control slices and slices pre-incubated in agatoxin TK (CCK-mediated decrease in euIPSC amplitude, with respect to pre-CCK control responses: control slices: 27.1 ± 6.1%, n = 5; slices pre-incubated with agatoxin TK: 27.3 ± 5.3%, n = 5; P = 0.9; note that the CCK-induced increase in the proportion of failures after presynaptic spikes was also not different under the two conditions: control slices: 16.2 ± 1.8%, n = 5; slices pre-incubated with agatoxin TK: 16.9 ± 8.2%, n = 5; P = 0.94; CCK did not significantly decrease the amplitude of the successfully evoked events in either group: decrease in amplitude, with respect to pre-CCK baseline: control slices: 14.8 ± 6.8%, n = 5; slices pre-incubated with agatoxin TK: 12.1 ± 5.7%, n = 5; P = 0.76). Thus, our current data so far suggest that GABA release from PV + BCs is not required for the CCK-induced suppression of GABA release from CCK + BCs. A possible explanation for the differences between the results that gave rise to the two alternative hypotheses concerning CCK action on CCK + BCs (Fig. 1) is a potential age dependency of the effects on the PV + BCs. Namely, CCK-induced increase in GABA release associated with the direct CCK-mediated excitation of PV + BCs was reported to be transient (lasting about 3 min) in juvenile rats (postnatal 2-3 weeks; Földy et al. 2007 ), but longer lasting (>25 min) in young adult rats (postnatal 5-7 weeks; Karson et al. 2008) . Since the potentially longer lasting CCK-effects on PV + BCs in the young adults may result in a more pronounced 'spill-over' of GABA from the PV + BC synapses to the CCK + BC synapses on pyramidal cells, we carried out additional experiments to address the issue of age dependency. The data showed that CCK (500 nM) produced a significant but still transient increase in sIPSC frequency recorded in CA1 pyramidal cells from 7-week-old rats (pre-CCK control: 4.5 ± 0.7 Hz, n = 5; Peak: 12.2 ± 5.2 Hz, n = 5; Post-peak: 4.5 ± 0.9 Hz, n = 5). In fact, the CCK-induced increase in sIPSC frequency diminished to the pre-CCK control level within about 3 min in the young adult rats (sIPSC frequency 3-4 min after the peak: 6.48 ± 1.8 Hz; P = 0.19, with respect to pre-CCK control), similarly to what was reported for juvenile rats (see Földy et al. 2007 , Fig. 1B ; note that the magnitude of the effect was actually smaller in the older animals: young adults: 2.7-fold increase in sIPSC frequency; juveniles: 6.5-fold increase, Földy et al. 2007) . Therefore, these data suggest that it is unlikely that a more pronounced or prolonged CCK-mediated increase in GABA release from PV + BCs in the older animals caused the discrepancy between our current findings and previous reports (Karson et al. 2008 ) with regard to the underlying mechanisms of CCK-mediated decrease in GABA release from CCK + BCs (note that the CCK-induced decrease in GABA release from CCK + BCs was also not larger in postnatal 4-to 5-week-old animals compared to juveniles; see Földy et al. 2007 ).
Lack of involvement of GABA B receptors
According to the 'GABA B receptor hypothesis' (Karson et al. 2008) , GABA released from PV + BCs in response to CCK-mediated depolarization activates presynaptic GABA B receptors on CCK + BCs, leading to suppression of GABA release from CCK + BCs. Therefore, we next tested the role of GABA B receptors in the CCK effect on CCK + BC to pyramidal cell transmission. Consistent with previous studies , bath application of GABA B receptor agonist, baclofen (20 μM), caused a strong suppression of euIPSCs at CCK + BC to pyramidal cell synapses that was fully reversible after application of the GABA B receptor antagonist CGP 55845 (2 μM) ( Fig. 3A ; pre-baclofen: −29.9 ± 9.5 pA; baclofen: −0.4 ± 0.7 pA; CGP 55845: −48.3 ± 11.5 pA; n = 3; reduction by baclofen: 95.6 ± 1.3%, P = 0.001). Note the interesting increase in euIPSC amplitude in CGP55845 and baclofen, compared to the pre-baclofen control. As shown in Fig. 7 in Neu et al. (2007) , we previously had found no GABA B receptor-dependent tonic inhibition present at the CCK + BC to pyramidal cell synapse; indeed, additional experiments confirmed that (Fig. 2B) and presence of CGP 55845 (Fig. 3B) . C, the CB1 receptor antagonist AM251 (10 μM) was able to block the CCK-induced reduction in evoked unitary IPSCs even in the presence of 2 μM CGP 55845 (CCK: 500 nM). Error bars represent S.E.M., and the asterisks denote P < 0.05. CGP 55845 alone did not produce a change in euIPSCs (pre-CGP: 38.2 ± 17.1 pA; CGP: −37.4 ± 16.6 pA; n = 3, P = 0.30, data not shown). Therefore, CGP 55845 applied after baclofen appeared to have a different effect from when applied alone; the mechanism of these differential effects was not investigated in this paper.
Next, we examined whether CGP 55845 blocks the CCK-induced reduction in GABA release from CCK + BCs. In CGP 55845 (2 μM), CCK (500 nM) was still able to decrease the amplitude of euIPSCs ( Fig. 3B ; pre-CCK control: −59.4 ± 22.3 pA; CCK peak: −42.3 ± 13.8 pA; CCK post-peak: −54.1 ± 17.5 pA; reduction by CCK: 25.5 ± 3.6%, n = 5; P = 0.01). Furthermore, the degree of CCK-induced suppression of GABA release did not differ between slices perfused with ACSF lacking or containing CGP 55845 (CCK-induced decrease in euIPSC amplitude: control, without CGP 55845: 27.1 ± 6.1%, n = 5; CGP 55845: 25.5 ± 3.6%, n = 5; P = 0.82). In addition, the CB1 receptor antagonist AM251 (10 μM) abolished the CCK-induced reduction in euIPSCs at CCK + BC to pyramidal cell synapses not only in the absence ), but also in the presence of CGP 55845 (Fig. 3C : pre-CCK control: −72.9 ± 46.6 pA; CCK peak: −71.6 ± 43.7 pA; CCK post-peak: −70.5 ± 45.2 pA; reduction by CCK: 3.3 ± 7.9%, n = 3; P = 0.7). These data show that GABA B Rs are not involved in CCK-induced suppression of GABA release from CCK + BCs.
CCK attenuates GABA release at SCA synapses in a CB1 receptor dependent manner
Taken together, the data presented above are not consistent with the 'GABA B receptor hypothesis' of CCK action on CCK + BC to CA1 pyramidal cell transmission. In the final series of experiments, we verified that, as predicted by the 'CB1 receptor hypothesis' and reported previously , the CCK-induced decrease in the synaptic transmission between CCK + BC and CA1 pyramidal cell pairs is sensitive to CB1 receptor blockade. The experiments showed that CB1 receptors were also required for the CCK-mediated modulation of GABAergic transmission at dendritic synapses between CCK + interneurons and CA1 pyramidal cells. Specifically, paired recordings demonstrated that CCK (500 nM) attenuated the amplitude of euIPSCs at CCK + SCA (Fig. 4A ) to pyramidal cell synapses ( Fig. 4B ; pre-CCK control: −33.9 ± 7.8 pA; CCK peak: −22.0 ± 6.9 pA; CCK post-peak: −29.8 ± 7.7 pA; reduction by CCK: 39.5 ± 5.2%, n = 5; P = 0.001), and AM251 (10 μM) was able to abolish the CCK-induced reduction in euIPSCs at SCA to pyramidal cell synapses as well ( Fig. 4C ; euIPSC amplitude in the presence of CCK and AM251, with respect to control: CCK peak, 104.4 ± 6.9%; n = 4; P = 0.57). Therefore, GABA release from both the perisomatically projecting CCK + BCs and the dendritically projecting CCK + SCAs is attenuated by CCK through a CB1 receptor-dependent mechanism.
Discussion
The main findings of this study are as follows: (1) blockade of P/Q-type Ca 2+ channels that abolished GABA release from PV + BCs did not inhibit the CCK induced suppression of GABA release from CCK + BCs; (2) GABA B receptor antagonist did not reduce the CCK effect on GABA release from CCK + BCs; (3) CB1 receptor antagonist abolished the CCK-induced suppression of GABA release from CCK + BCs; and (4) CCK attenuated GABA release from dendritically projecting CCK + SCAs, and the latter effect also required CB1 receptors. Taken together, these results indicate that CCK modulates GABA release from the presynaptic terminals of CCK + interneurons along the somato-dendritic axis of postsynaptic CA1 pyramidal cells through endocannabinoid signalling, and not through heterosynaptic GABA B receptor mediated action requiring GABA release from PV + BCs.
CCK attenuates GABA release from CCK expressing interneurons through a CB1 receptor dependent pathway
CCK is one of the most abundant and widely distributed neuropeptides in the brain, involved in a diversity of behaviours such as learning and memory, feeding, nociception, and satiety, and it is also implicated in several brain disorders including anxiety, panic attacks, deficits in fear extinction, schizophrenia and epilepsy (Noble & Roques, 2006; Lee & Soltesz, 2011) . In spite of its abundance, recent results indicate that CCK regulates perisomatic GABAergic inhibition in a highly cell type specific manner through the actions of G-protein coupled CCK B receptors Karson et al. 2008) , by enhancing the rate of GABA release from PV + BCs while inhibiting GABA release from CCK + BCs. Therefore, CCK, beyond serving as a convenient marker for one of the two types of BCs, also acts as a finely tuned molecular switch regulating BC functions.
However, the precise mechanisms underlying the dual effects of CCK on BC outputs are not understood. There is general agreement that CCK, starting at low nanomolar concentrations, increases the firing rates of PV + BCs. The increased action potential discharge of PV + BCs in response to CCK is known to result in an enhancement of the frequency of spontaneous IPSCs (sIPSCs) in the CA1 pyramidal cells (for a quantification of the CCK induced increase in sIPSC frequency, see Fig. 1b in Földy et al. 2007 ; see also the sIPSCs visible on the example traces in Figs 2B and 4B in the current study, panels 'Peak' versus 'Control'). The effect of CCK on sIPSC frequency in CA1 pyramidal cells can be abolished by P/Q channel antagonists (Figs. 1a and b in Földy et al. 2007 and Fig. 4a in Karson et al. 2008) , in agreement with the involvement of PV + BCs as the major sources of GABA underlying the increased sIPSC. However, in contrast to the direct actions of CCK on PV + BCs, the inhibitory effect of CCK on GABA release from CCK + BCs is controversial, with two alternative, albeit not necessarily mutually exclusive, pathways proposed to explain the cellular mechanisms underlying the effect (Fig. 1) . Our paired recording data presented in this paper are consistent with the 'CB1 receptor hypothesis' of CCK action. CCK B receptors are thought to act typically through the G q/11 second messenger pathway, and thus, similarly to other G q/11 -linked receptors including metabotropic glutamate and M1/3 muscarinic receptors, their activation would be predicted to enhance the synthesis of endocannabinoids and the retrograde inhibition of GABA release through the activation of presynaptic CB1 receptors (Kano et al. 2009 ). In agreement with the latter prediction, we confirmed our previous results ) that CB1 receptor blockade abolishes the CCK effect on GABA release from the synaptic terminals of pair recorded presynaptic CCK + BCs, and our experiments with SCAs extend the requirement for CB1 receptors for CCK action to dendritic CCK + synapses as well. Furthermore, consistent with the suggestion that the source of the endocannabinoids is likely to be the postsynaptic pyramidal cells themselves, inhibition of G-protein coupled receptor function with the postsynaptic injection of the non-hydrolysable GDP analogue GDP-βS was previously shown to result in a blockade of the CCK induced suppression of GABA release from the CCK + BCs .
In contrast, our data are not consistent with the 'GABA B receptor hypothesis' of CCK action on CCK + BC to pyramidal cell transmission. Indeed, the lack of effect of either agatoxin TK or CGP 55845 on the CCK induced suppression of GABA release from CCK + BCs in this study suggests that the excitatory action of CCK on PV + BCs is mechanistically unrelated to the inhibitory CCK action on the CCK + BC to CA1 pyramidal cell transmission. It should be noted that the 'GABA B receptor hypothesis' was originally proposed based on a series of pharmacological observations on CCK actions on endocannabinoid sensitive and insensitive sIPSCs in single cell recording experiments from CA1 pyramidal cells in the presence of carbachol in the perfusing medium (Karson et al. 2008) . While it is difficult to discern precisely which experimental condition was responsible for the observations that led to the 'GABA B receptor hypothesis' by Karson and colleagues (2008) , it seems likely that the differences are mainly due to the employment of single pyramidal cell recording methods versus paired recording techniques from anatomically and immunocytochemically identified interneurons, as the latter approach allows for a better isolation and more direct control of the GABAergic synaptic transmission from PV + or CCK + BCs onto CA1 pyramidal cells. Our results do not exclude that GABA released from PV + terminals may be able to reach CCK + terminals under some circumstances. Indeed, the two types of BC synapses can be in close proximity (Karson et al. 2009 ), although it is important to note that the overall somato-dendritic distribution patterns of PV + versus CCK + terminals from BCs on the perisomatic regions of pyramidal cells are not identical .
In summary, our data support the requirement for CB1 receptors in the CCK mediated regulation of GABA release from somatic and dendritic CCK + synapses. It is interesting in this regard that both CB1 and CCK receptors have been implicated in mood-related disorders (Freund & Katona, 2007; Lee & Soltesz, 2011) , and endocannabinoid and CCK signalling systems have been reported to be able to closely interact to modulate anxiety, stress and fear extinction (Kurrikoff et al. 2008; Chhatwal et al. 2009) . Future studies will be needed to determine the precise role of hippocampal CCK + interneuronal microcircuits in limbic system functions influenced by interacting CCK and CB1 receptor-dependent pathways.
